(Source: Cancer Management and Research)
In this study, we investigated the distinct expression and prognostic value of immunoinhibitors in patients with PC by analyzing a series of databases, including TISIDB, GEPIA, cBioPortal, and Kaplan-Meier plotter database. The mRNA expression levels of IDO1, CSF1R, VTCN1, KDR, LGALS9, TGFBR1, TGFB1, IL10RB, and PVRL2 were found to be significantly upregulated in patients with PC. Aberrant expression of TGFBR1, VTCN1, and LGALS9 was found to be associated with the worse outcomes of patients with...
Authors: Wei M, Du Y, Wu X, Su Q, Zhu J, Zheng L, Lv G, Zhuang J Abstract The classification of benign and malignant based on ultrasound images is of great value because breast cancer is an enormous threat to women's health worldwide. Although both texture and morphological features are crucial representations of ultrasound breast tumor images, their straightforward combination brings little effect for improving the classification of benign and malignant since high-dimensional texture features...
Conclusion: This study determined that combined TIL and anti-PD1 therapy is safe and effective in metastatic osteosarcoma patients with chemotherapy resistance. PMID: 33062726 [PubMed - in process] (Source: Journal of Immunology Research)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
STK3 Suppresses Ovarian Cancer Progression by Activating NF-κB Signaling to Recruit CD8+ T-Cells. J Immunol Res. 2020;2020:7263602 Authors: Wang X, Wang F, Zhang ZG, Yang XM, Zhang R Abstract Serine/threonine protein kinase-3 (STK3) is a critical molecule of the Hippo pathway but little is known about its biological functions in the ovarian cancer development. We demonstrated the roles of STK3 in ovarian cancer. Existing databases were used to study the expression profile...
Authors: Peng T, Wang T, Liu G, Zhou L Abstract Glioblastoma (GBM) is an aggressive brain tumor with shorter median overall survival time. It is urgent to find novel methods to enhance the therapeutic efficiency clinically. miR-373 is related to the biological development process of cancers, but there are no reports whether modulation on miR-373 could affect GBM development or modify the efficiency of chemo- or radiotherapy yet. Our current study found that the higher level of miR-373 was...
Corrigendum to "PIPKIγ Regulates CCL2 Expression in Colorectal Cancer by Activating AKT-STAT3 Signaling". J Immunol Res. 2020;2020:1786505 Authors: Xue J, Ge X, Zhao W, Xue L, Dai C, Lin F, Peng W Abstract [This corrects the article DOI: 10.1155/2019/3690561.]. PMID: 33062718 [PubMed] (Source: Journal of Immunology Research)
Authors: Wertel I, Suszczyk D, Pawłowska A, Bilska M, Chudzik A, Skiba W, Paduch R, Kotarski J Abstract Ovarian cancer (OC) is one of the deadliest gynecological cancers. Recent studies suggest a crucial role of inflammatory immune system cells in the progression and metastasis of OC. The understanding of inflammatory mechanisms is pivotal for the selection of a biomarker that allows the differentiation between malignant and benign tumors, monitoring the progression of the disease, and...
Mark above section as read
Mark above section as read
The PDs are downloading applications today. How are the numbers looking or is nobody talking? (Source: Student Doctor Network)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
The therapists are essentially the radiation oncologists (because the derms can’t be bothered with the XRT physics-y stuff). These centers are on average much busier than “average” PP rad onc clinic. Imho. As Zeitman says (?) better to own a disease site than a modality. Especially since it seems we don’t own either? Turnkey Implementation Services | Skin Cure CONTACT US 630.601.4060 * SRT THAT...
Medical student praise has gone to a whole new public level. I'm sure internally and privately these recommendations are an important part of residency recruitment, but this level of public brown nosing is just sickening. Welcome to the family? The family that will turn their back to you and barely remember you 5 years from now? I'd like to see them tweet out this type of praise for their own... Medical student praise...misguided? (Source: Student Doctor Network)
Mark above section as read
Abstract Background Patients with cancer often receive acid-suppressive agents (ASAs) to treat common gastroesophageal reflux and peptic ulcer diseases. Our systematic review addresses the association between ASAs and survival outcomes in these patients. Methods We searched MEDLINE, EMBASE, and Cochrane until December 2019, including randomized controlled...
Abstract Background In a randomized pivotal global phase III study, S-1 and oxaliplatin 100 mg/m2 (SOX100) combination chemotherapy was as effective as S-1 and cisplatin for advanced gastric cancer (AGC) and showed a favorable safety profile. In this phase II study, we analyzed survival outcomes to assess the efficacy and safety of the SOX regimen with oxaliplatin 130 mg/m2 (SOX130) in AGC. ...
Abstract Coronavirus disease 2019 (COVID-19) was declared to be a global pandemic by the World Health Organization on March 11, 2020. On April 7, 2020, a state of emergency was declared in Japan, as had been by other nations worldwide. This unprecedented crisis has profound implications for patients undergoing chemotherapy and for practicing healthcare professionals. Various reports have shown data indicating that cancer patients with COVID-19 have high morbidity and mortality...
Mark above section as read
Grants to coordinate and expand evidence-based preventionservices and cancer screening for underserved and rural areas of Texas without adequate access to healthcare. Geographic coverage: Texas -- Cancer Prevention and Research Institute of Texas (Source: Funding opportunities via the Rural Health Information Hub)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Mark above section as read
Condition: Colorectal Cancer Interventions: Drug: Oral Sulfate Tablet(ORA·FANGⓇ); Drug: Sodium Picosulfate Solution(PicosolutionⓇ) Sponsors: National Cancer Center, Korea; Seoul National University Hospital; Seoul National University Bundang Hospital; Daehang Hospital Recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Conditions: Biliary Obstruction; Pancreatic Cancer; Biliary Tract Neoplasms Interventions: Device: Double pigtail plastic stent through lumen-apposing metal stent; Device: Lumen-apposing metal stent without double pigtail plastic stent Sponsors: Hospital Universitari de Bellvitge; Hospital Mutua de Terrassa; Hospital del Río Hortega; Hospital Clínico Universitario de Valencia; Hospital General Universitario de Alicante; Hospital Universitario Ramon y Cajal; Hospital Provincial de Castellon...
Conditions: T-cell Acute Lymphoblastic Leukemia; T-cell Non-Hodgkin Lymphoma Intervention: Drug: anti-CD5 CAR T cells Sponsors: iCell Gene Therapeutics; iCAR Bio Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Melanoma Interventions: Other: Immunotherapy; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Condition: Head and Neck Cancer Intervention: Other: Submandibular Gland Stem Cell Transplantation Sponsor: University Medical Center Groningen Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: Thyroid Cancer; Thyroid Cancer, Papillary; Benign Thyroid Tumor Interventions: Other: Identification group; Other: Validation group Sponsor: Chang Gung Memorial Hospital Completed (Source: ClinicalTrials.gov)
Condition: Colorectal Cancer Interventions: Procedure: Trimodal rehabilitation + ERAS; Procedure: ERAS + nutritional prehabilitation Sponsors: St. Borbala Hospital; Biological Research Centre, Szeged Recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Condition: Antibiotic Resistant Strain Intervention: Other: FMT Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Major Depressive Disorder Intervention: Drug: Psilocybin Sponsor: Maryland Oncology Hematology, PA Recruiting (Source: ClinicalTrials.gov)
Conditions: Radiodermatitis; Radiation Toxicity; Radiation Dermatitis; Skin Diseases; Head and Neck Cancer Intervention: Device: Cavilon Advanced Skin Protectant Sponsor: Jessa Hospital Recruiting (Source: ClinicalTrials.gov)
Condition: Breast Cancer Intervention: Behavioral: Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Sponsor: University of Utah Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Condition: Cachexia Intervention: Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: Colorectal Cancer Metastatic; Liver Metastasis Colon Cancer Interventions: Drug: FOLFOX regimen; Biological: Anti-EGFR or Bevacizumab; Drug: LIVERPEARLS-Irinotecan Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: Breast Cancer Female; Early-stage Breast Cancer Interventions: Procedure: Lumpectomy; Radiation: Intraoperative Radiation Therapy Sponsor: Navicent Health Recruiting (Source: ClinicalTrials.gov)
Conditions: Ovarian Cancer; Oligometastatic Disease; Recurrent Ovary Cancer; Persistent Intervention: Radiation: Stereotactic body radiotherapy Sponsors: Gemelli Molise Hospital; Fondazione Policlinico Universitario A. Gemelli, IRCCS Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Prostate Cancer Intervention: Sponsor: Ipsen Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: Gastric Cancer; Surgery Intervention: Procedure: ICG near-infrared imaging Sponsor: Fujian Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Bladder Cancer Intervention: Other: High-Intensity Interval Training Sponsors: University of Alberta; Northern Alberta Urology Centre; Cross Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
Condition: Cancer Interventions: Behavioral: Telehealth visits; Behavioral: Standard of Care Sponsor: University of California, Davis Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Malignant Melanoma Intervention: Drug: Camrelizumab for injection Sponsor: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: Colorectal Cancer; Fragility; Elderly Intervention: Procedure: surgery Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Completed (Source: ClinicalTrials.gov)
Condition: Pancreas Cancer Interventions: Drug: Folfirinox; Drug: Gemcitabine; Radiation: radiation therapy; Procedure: Pancreatectomy Sponsor: University of Cincinnati Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Prostate Cancer Intervention: Radiation: SBRT Sponsor: Institute of Cancer Research, United Kingdom Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
Conditions: Neoplasm, Esophagus; Malignant Esophagus Tumor; Neoplasm, Esophageal Intervention: Combination Product: Bintrafusp alfa Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Malignant Female Reproductive System Neoplasm Interventions: Procedure: Biospecimen Collection; Behavioral: BrainCheck Cognitive Assessment; Procedure: Cognitive Assessment; Procedure: Electroencephalography Sponsor: M.D. Anderson Cancer Center Recruiting (Source: ClinicalTrials.gov)
Conditions: HER2-negative Breast Cancer; Triple Negative Breast Cancer Interventions: Drug: Capecitabine; Drug: Carboplatin; Drug: Cisplatin; Drug: Sacituzumab govitecan Sponsors: German Breast Group; Immunomedics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Lung Carcinoma Interventions: Other: Educational Intervention; Other: Questionnaire Administration; Other: Survey Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Condition: Metastatic Disease Intervention: Device: 3DCRT, IMRT, VMAT, SBRT Sponsor: National Cancer Institute, Naples Recruiting (Source: ClinicalTrials.gov)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
Conditions: Parathyroid Diseases; Thyroid Diseases; Liver Cancer; Liver Metastases; Digestive Cancer; Digestive Perfusion Intervention: Other: Hyperspectral Imaging Sponsors: IHU Strasbourg; ARC Foundation for Cancer Research Recruiting (Source: ClinicalTrials.gov)
Condition: Non-small Cell Lung Cancer Intervention: Sponsor: University Hospital, Lille Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Uveal Melanoma Interventions: Drug: PAC-1; Drug: Entrectinib Sponsors: Arkadiusz Z. Dudek, MD; HealthPartners Regions Cancer Care and Frauenshuh Cancer Care Centers; Vanquish Oncology, Inc.; Genentech, Inc.; Midwest Melanoma Partnership Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Pancreatic Cancer Intervention: Device: Point-of-care Portable Perfusion Phantom, P4 Sponsor: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: Breast Cancer; Prostate Cancer; Colorectal Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer; Stage I Prostate Cancer; Stage II Prostate Cancer; Stage III Prostate Cancer; Stage I Colorectal Cancer; Stage II Col orectal Cancer; Stage III Colorectal Cancer Intervention: Other: Exercise Sponsor: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine?...
Condition: Advanced Cancer Interventions: Behavioral: Couple Communication Skills Training; Behavioral: Healthy Lifestyle Information Sponsor: Duke University Recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Condition: Ovarian Cancer Interventions: Drug: Apatinib Mesylate; Drug: Abraxane; Drug: Cis Platinum; Drug: Carboplatin Sponsor: Zhongshan Hospital Xiamen University Recruiting (Source: ClinicalTrials.gov)
Condition: Bladder Cancer Interventions: Drug: Chemotherapy; Diagnostic Test: Immediate Multiparametric MRI; Procedure: Cystectomy and Lymphadenectomy; Diagnostic Test: conventional Multiparametric MRI; Diagnostic Test: Baseline Multiparametric MRI Sponsor: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Condition: Breast Cancer Intervention: Diagnostic Test: screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori Recruiting (Source: ClinicalTrials.gov)
Condition: Incidence Rate of Perioperiative Venous Thromboembolism(VTE) in Colorectal Cancer Patients Intervention: Sponsor: Beijing Friendship Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Squamous Cell Carcinoma of the Head and Neck Interventions: Drug: Monalizumab; Drug: Cetuximab Sponsors: AstraZeneca; Innate Pharma Recruiting (Source: ClinicalTrials.gov)
Condition: Cancer Intervention: Drug: 99mTc-MIRC208 Sponsor: Beijing Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Condition: Colorectal Cancer Intervention: Drug: Influenza Vaccines Sponsors: Zealand University Hospital; University of Copenhagen Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Condition: Gastric Cancer Intervention: Drug: Indocyanine green Sponsor: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Cervical Cancer Interventions: Procedure: The concurrent 3 weeks TP regimen; Procedure: The concurrent weekly TP regimen; Radiation: External radiation plus intraluminal after-loading irradiation Sponsor: Chongqing University Cancer Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Conditions: Prostate Cancer Metastatic; Radiotherapy Side Effect; Surgery; Urologic Cancer; Quality of Life; Patient Satisfaction; Health Care Utilization Interventions: Other: Semi-Structured Interview Healthcare Professional; Other: Semi-Structured Interview Patients; Other: Think Aloud Interview Patients; Other: Discrete Choice Experiment (DCE) Patients Sponsors: Imperial College London; University of Aberdeen Not yet recruiting (Source: ClinicalTrials.gov)
Condition: HER2-negative Breast Cancer Interventions: Drug: AZD9833; Drug: Fulvestrant Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Condition: Gastric Cancer Stage IV Intervention: Drug: olaparib+pembrolizumab+paclitaxel Sponsor: Yonsei University Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Hematologic Malignancies Intervention: Drug: GFH009 Sponsor: Zhejiang Genfleet Therapeutics Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Viscera; Metastatic Prostate Carcinoma; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 Interventions: Drug: Cabazitaxel; Drug: Carboplatin; Biological: Cetrelimab;...
Condition: Cervical Cancer Intervention: Biological: The study being observational in nature, there is no intervention. The investigators will only collect cervical samples from married women within a specified age range at different intervals. Sponsors: International Agency for Research on Cancer; Department of Health and Family welfare, Government of Sikkim; Sikkim Manipal Institute; Rajiv Gandhi Centre for Biotechnology Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Pancreas Cancer Interventions: Diagnostic Test: Abbreviated PB MRI; Genetic: Gene mutation test; Diagnostic Test: Conventional follow-up Sponsors: Seoul National University Hospital; National Research Foundation of Korea Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Conditions: Cancer; Thoracic Neoplasms; Gastrointestinal Cancer; Lung Cancer Intervention: Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; WellSpan Health Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: Lung Cancer, Non-small Cell; EGFR T790M; EGFR Gene Mutation Interventions: Drug: Almonertinib; Drug: Pemetrexed; Drug: Carboplatin Sponsor: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: Gastrointestinal Neoplasms; Esophagogastric Junction Interventions: Drug: Durvalumab; Drug: FLOT chemotherapy Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Nasopharyngeal Carcinoma Intervention: Procedure: Trans-oral magnifying endoscopy with NBI Sponsor: Chinese University of Hong Kong Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Solid Tumor Interventions: Drug: SHR2150; Drug: Anti-Cancer Agent Sponsor: Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Condition: Smoking Interventions: Behavioral: Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach.; Drug: Nicotine Replacement Therapy; Drug: Varenicline; Other: Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy) Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI); National Institutes of Health (NIH) Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have...
Condition: Hepatocellular Carcinoma Non-resectable Intervention: Drug: TACE combined with sintilimab and bevacizumab Sponsor: Second Affiliated Hospital of Guangzhou Medical University Recruiting (Source: ClinicalTrials.gov)
Conditions: Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Oral Cavity Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Resectable Oropha ryngeal Squamous Cell Carcinoma Intervention: Biological: Efineptakin alfa Sponsors: Hyunseok Kang, MD; NeoImmuneTech Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: If you are looking to buy something...
Condition: HCC Intervention: Drug: Cabozantinib Sponsor: Stephen Chan Lam Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Prostate Cancer Intervention: Radiation: SBRT Sponsor: Institute of Cancer Research, United Kingdom Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Malignant Female Reproductive System Neoplasm Interventions: Procedure: Biospecimen Collection; Behavioral: BrainCheck Cognitive Assessment; Procedure: Cognitive Assessment; Procedure: Electroencephalography Sponsor: M.D. Anderson Cancer Center Recruiting (Source: ClinicalTrials.gov)
Condition: Antibiotic Resistant Strain Intervention: Other: FMT Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: Colorectal Cancer; Fragility; Elderly Intervention: Procedure: surgery Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Completed (Source: ClinicalTrials.gov)
Condition: Colorectal Cancer Interventions: Drug: Oral Sulfate Tablet(ORA·FANGⓇ); Drug: Sodium Picosulfate Solution(PicosolutionⓇ) Sponsors: National Cancer Center, Korea; Seoul National University Hospital; Seoul National University Bundang Hospital; Daehang Hospital Recruiting (Source: ClinicalTrials.gov)
Condition: Metastatic Disease Intervention: Device: 3DCRT, IMRT, VMAT, SBRT Sponsor: National Cancer Institute, Naples Recruiting (Source: ClinicalTrials.gov)
Condition: Prostate Cancer Intervention: Sponsor: Ipsen Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Pancreas Cancer Interventions: Drug: Folfirinox; Drug: Gemcitabine; Radiation: radiation therapy; Procedure: Pancreatectomy Sponsor: University of Cincinnati Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Head and Neck Cancer Intervention: Other: Submandibular Gland Stem Cell Transplantation Sponsor: University Medical Center Groningen Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: T-cell Acute Lymphoblastic Leukemia; T-cell Non-Hodgkin Lymphoma Intervention: Drug: anti-CD5 CAR T cells Sponsors: iCell Gene Therapeutics; iCAR Bio Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Condition: Major Depressive Disorder Intervention: Drug: Psilocybin Sponsor: Maryland Oncology Hematology, PA Recruiting (Source: ClinicalTrials.gov)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
Conditions: Radiodermatitis; Radiation Toxicity; Radiation Dermatitis; Skin Diseases; Head and Neck Cancer Intervention: Device: Cavilon Advanced Skin Protectant Sponsor: Jessa Hospital Recruiting (Source: ClinicalTrials.gov)
Conditions: Gastric Cancer; Surgery Intervention: Procedure: ICG near-infrared imaging Sponsor: Fujian Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: Biliary Obstruction; Pancreatic Cancer; Biliary Tract Neoplasms Interventions: Device: Double pigtail plastic stent through lumen-apposing metal stent; Device: Lumen-apposing metal stent without double pigtail plastic stent Sponsors: Hospital Universitari de Bellvitge; Hospital Mutua de Terrassa; Hospital del Río Hortega; Hospital Clínico Universitario de Valencia; Hospital General Universitario de Alicante; Hospital Universitario Ramon y Cajal; Hospital Provincial de Castellon...
Condition: Colorectal Cancer Interventions: Procedure: Trimodal rehabilitation + ERAS; Procedure: ERAS + nutritional prehabilitation Sponsors: St. Borbala Hospital; Biological Research Centre, Szeged Recruiting (Source: ClinicalTrials.gov)
Condition: Cachexia Intervention: Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
Conditions: HER2-negative Breast Cancer; Triple Negative Breast Cancer Interventions: Drug: Capecitabine; Drug: Carboplatin; Drug: Cisplatin; Drug: Sacituzumab govitecan Sponsors: German Breast Group; Immunomedics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: Thyroid Cancer; Thyroid Cancer, Papillary; Benign Thyroid Tumor Interventions: Other: Identification group; Other: Validation group Sponsor: Chang Gung Memorial Hospital Completed (Source: ClinicalTrials.gov)
Conditions: Breast Cancer Female; Early-stage Breast Cancer Interventions: Procedure: Lumpectomy; Radiation: Intraoperative Radiation Therapy Sponsor: Navicent Health Recruiting (Source: ClinicalTrials.gov)
Condition: Breast Cancer Intervention: Behavioral: Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Sponsor: University of Utah Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Lung Carcinoma Interventions: Other: Educational Intervention; Other: Questionnaire Administration; Other: Survey Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Condition: Malignant Melanoma Intervention: Drug: Camrelizumab for injection Sponsor: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: Colorectal Cancer Metastatic; Liver Metastasis Colon Cancer Interventions: Drug: FOLFOX regimen; Biological: Anti-EGFR or Bevacizumab; Drug: LIVERPEARLS-Irinotecan Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Cancer Interventions: Behavioral: Telehealth visits; Behavioral: Standard of Care Sponsor: University of California, Davis Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: Neoplasm, Esophagus; Malignant Esophagus Tumor; Neoplasm, Esophageal Intervention: Combination Product: Bintrafusp alfa Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Bladder Cancer Intervention: Other: High-Intensity Interval Training Sponsors: University of Alberta; Northern Alberta Urology Centre; Cross Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
Condition: Melanoma Interventions: Other: Immunotherapy; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Conditions: Ovarian Cancer; Oligometastatic Disease; Recurrent Ovary Cancer; Persistent Intervention: Radiation: Stereotactic body radiotherapy Sponsors: Gemelli Molise Hospital; Fondazione Policlinico Universitario A. Gemelli, IRCCS Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Conditions: Lung Cancer Stage IV; Lung Cancer, Non-small Cell; Hepatitis Intervention: Other: No intervention due to observational methods of study Sponsors: Western Sydney Local Health District; University of Western Sydney Recruiting (Source: ClinicalTrials.gov)
Mark above section as read
Introduction: Gastric cancer (GC) is an aggressive disease with high mortality rates. Lymph node (LN) staging of GC is a major source of controversy. The aim of this study is to compare the prognostic value of 3 different LN classifications for patients with resected GC: the eighth TNM staging system, lymph node ratio (LNR, ratio between positive and total LN) and a new anatomic-based classification (Choi classification). Materials and Methods: A retrospective study of all cases of GC resected...
Objective: Neoadjuvant chemoradiation (NA-CRT), followed by resection of high-risk soft tissue sarcoma (STS), may offer good disease control and toxicity outcomes. We report on a single institution’s modern NA-CRT experience. Materials and Methods: Delay to surgical resection, resection margin status, extent of necrosis, tumor cell viability, presence of hyalinization, positron emission tomography (PET)/computed tomography data, and treatment toxicities were collected. Using the Kaplan-Meier...
Mark above section as read
Purpose:Pediatric high-grade glioma (pHGG) diagnosis portends poor prognosis and therapeutic monitoring remains difficult. Tumors release cell-free tumor DNA (cf-tDNA) into cerebrospinal fluid (CSF), allowing for potential detection of tumor-associated mutations by CSF sampling. We hypothesized that direct, electronic analysis of cf-tDNA with a handheld platform (Oxford Nanopore MinION) could quantify patient-specific CSF cf-tDNA variant allele fraction (VAF) with improved speed and limit of detection...
Purpose: We assessed the efficacy and safety of camrelizumab (an anti-PD-1 monoclonal antibody) plus apatinib (a vascular endothelial growth factor [VEGFR]-2 tyrosine kinase inhibitor) in patients with advanced hepatocellular carcinoma (HCC). Patients and Methods: This non-randomized, open-label, multicenter, phase 2 study enrolled patients with advanced HCC who were treatment-naive or refractory/intolerant to first-line targeted therapy. Patients received intravenous camrelizumab 200 mg (for bodyweight...
Background: Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC) and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab efficacy in optimally selected patients using highly sensitive BEAMing, capable of detecting alterations below standard clinical assays. Methods: CO.17 compared cetuximab versus best supportive care (BSC) in RAS/BRAF unselected mCRC. We performed RAS/BRAF...
Purpose: Immunomonitoring of chimeric antigen receptor (CAR) T cells relies primarily on their quantification in the peripheral blood, which inadequately quantifies their biodistribution and activation status in the tissues. Non-invasive molecular imaging of CAR T cells by positron emission tomography (PET) is a promising approach with the ability to provide spatial, temporal and functional information. Reported strategies rely on the incorporation of reporter transgenes or ex vivo biolabeling, significantly...
Purpose: Concurrent gemcitabine and nab-paclitaxel treatment is one of the preferred chemotherapy regimens for metastatic and locally-advanced pancreatic ductal adenocarcinoma (PDAC). Previous studies demonstrate that caveolin-1 (Cav-1) expression is critical for nab-paclitaxel uptake into tumors and correlates with response. Gemcitabine increases nab-paclitaxel uptake by increasing Cav-1 expression. Thus, we hypothesized that pre-treatment with gemcitabine would further enhance the sensitivity of...
Purpose: Here we investigated the impact of oncolytic HSV (oHSV) treatment on cisplatin sensitivity of platin resistant ovarian cancer (OC), and the impact of the combination on immunotherapy. Experimental Design: Therapeutic efficacy of the combination was assessed in platin resistant human and murine OC peritoneal metastatic mouse models (n=9-10/group). RNA sequencing along with flow cytometry of splenocytes from treated mice was employed to examine the effect of anti-tumor immune response (n=3/group)....
Mark above section as read
As the ground war in Vietnam escalated in the late 1960s, the US government leveraged the so-called doctor draft to secure adequate numbers of medical personnel in the armed forces. Among newly minted physicians ’ few alternatives to military service was the Clinical Associate Training Program at the National Institutes of Health. Though only a small percentage of applicants were accepted, the elite program launched an unprecedented number of remarkable scientific careers that would revolutionize...
Mark above section as read
Few Americans are aware of a major epidemic that has taken hold of large areas of their country in recent years – by a disease that is easily diagnosed and prevented. Sadly, public – and even professional interest in these events have been overshadowed by COVID-19. AN UPTICK IN CASES Hepatitis A had been largely under control until three years ago and can be easily prevented through the use of a safe and effective vaccine. From January 2017 to January 2019, at least 26 separate outbreaks...
For a bunch of folks striving to stomp out malignant processes in our patients, we sure tolerate a fair amount of destructive behavior among training programs. I ’ll be the first to say I’m not the most delicate flower in the garden. Before pursuing medicine, I was a college athlete. I’m no stranger to long hours, […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more. (Source: Kevin, M.D. - Medical Weblog)
Researchers at the Max Planck Institute and the University of Stuttgart in Germany have developed a method to create high-resolution ultrasound fields, a capability which may improve the effectiveness of ultrasound therapies and tailor them for individual patients. The technique involves passing ultrasonic waves through water, where hydrogen bubbles help to transform the waves into desired shapes. High-power ultrasound therapy is currently used to destroy tumor tissues, including prostate...
Chromatin is the name given to the packed structure of nuclear DNA and surrounding molecules, tightly coiled in the center of the cell. Chromatin structure and the molecules responsible for regulating that structure are a part of the complex epigenetic systems that determine the pace of protein production, and thus cell behavior. Chromatin changes in characteristic ways with age, a situation that is far from fully mapped and understood, but is particularly important in stem cell aging. Stem cell...
A third of all people will be a caregiver at some point in their lives. Caregiving for people with schizophrenia presents challenges that many people are ill-prepared for. Host Rachel Star breaks down the principles of caregiving and creative ways to navigate schizophrenia. Dr. Sarah Kopelovich joins to share schizophrenia caregiver specific training. About our Guest Sarah Kopelovich, PhD is a forensically-trained licensed clinical psychologist in the Department of Psychiatry and Behavioral...
Artificial Intelligence (A.I.) has for long been the subject of the fertile minds of science-fiction writers and movie directors. HAL 9000, Skynet and JARVIS are some of the many A.I. names sci-fi enthusiasts are familiar with. They streamline administrative tasks, entertain humans and, of course, become overlords threatening human existence. Now, thanks to technological progress, such A.I. are breaking out of the confines of movies and books and into healthcare. While they aren’t threatening...
In conclusion, all NAFLD histological stages were associated with significantly increased overall mortality, and this risk increased progressively with worsening NAFLD histology. Most of this excess mortality was from extrahepatic cancer and cirrhosis, while in contrast, the contributions of cardiovascular disease and HCC were modest. (Source: Fight Aging!)
Mapping mammalian biochemistry is a sizable task, and much of that biochemistry remains poorly understood and categorized. Cell signaling is a vast topic in and of itself. Here researchers discuss myokines, signal molecules generated by muscle cells as a result of exercise. These diverse signals are influential on tissue function and health, and mediate some fraction of the benefits resulting from physical activity. Further, some clearly change in abundance with age, and might therefore be useful...
Mark above section as read
ConclusionsP26, as a novel TIM3-binding peptide, has the ideal bioactivity connecting to TIM3 and the potential prospect of application in immunotherapy as an alternative or adjuvant to existing agents. (Source: Cancer Chemotherapy and Pharmacology)
ConclusionIt can be concluded that 20-mg and 100-mg capsules of TOZ309 are bioequivalent to Temodal® capsules of the same strength under fasting conditions.Trial registrationhttps://www.chinadrugtrials.org.cn/index.html, CTR2017 0122. (Source: Cancer Chemotherapy and Pharmacology)
Mark above section as read
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print. (Source: Cancer Biotherapy and Radiopharmaceuticals)
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print. (Source: Cancer Biotherapy and Radiopharmaceuticals)
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print. (Source: Cancer Biotherapy and Radiopharmaceuticals)
Mark above section as read
Pathologists are responsible for selecting the assays for the optimal identification of patients for targeted therapy. The current paradigm of regulatory assay approval is that when a clinical trial involving a drug and a biomarker, using a specific assay to identify patients that might respond to the drug, meets its endpoint, the assay is approved concomitantly as a companion diagnostic. Private health insurance bodies or public health systems then decide on reimbursement of the assay when they...
Mark above section as read
ConclusionDynamics of NLR have a prognostic value in stage III NSCLC treated with definitive CRT. Pre- and post-CRT NLR should be evaluated in prospective clinical trials involving consolidation treatment with immunotherapy. (Source: Clinical and Translational Oncology)
ConclusionThe presence of LVSI was highlighted as a variable significant to survival. In further clinical practice, patients with LVSI may need more intensive treatment in certain populations. (Source: Clinical and Translational Oncology)
ConclusionsTargeting CTLA-4 may be a potential novel therapeutic strategy for chordoma patients. (Source: Clinical and Translational Oncology)
ConclusionsPopulation-based data show that external beam radiotherapy is underutilized in Catalonia. This situation requires a careful analysis to understand the causes, as well as an improvement of the available resources, oriented toward achieving realistic targets for the optimal use of external beam radiotherapy in our country. (Source: Clinical and Translational Oncology)
ConclusionThe study suggests that FAM83H overexpression predicts poor prognosis and correlates with less CD8+ T cells infiltration and Ras-PI3K-Akt-mTOR signaling pathway in PC. (Source: Clinical and Translational Oncology)
ConclusionBrigatinib demonstrated modest activity in crizotinib-resistant ROS1-rearranged NSCLC. Its intracranial and systemic activity should be assessed in correlation with the underlying molecular mechanism of crizotinib resistance. (Source: Clinical and Translational Oncology)
ConclusionThis study illustrated that tumors in the oropharynx, lower age, adjuvant chemoradiation and radiation, and microscopic margins were associated with greater survival. (Source: Clinical and Translational Oncology)
AbstractCircular RNAs (circRNAs) have been considered a special class of non-coding RNAs without 5 ′ caps and 3′ tails which are covalently closed RNA molecules generated by back splicing of mRNA. For a long time, circRNAs have been considered to be directly involved in various biological processes as functional RNA. In recent years, a variety of circRNAs have been found to have translational functions, and the resultant peptides also play biological roles in the emergence and progression of human...
ConclusionDCST1-AS1 may downregulate miR-29b through methylation in GBM to promote cancer cell proliferation. (Source: Clinical and Translational Oncology)
AbstractRadiotherapy is the treatment of choice for many cancer patients. Residual tumor leads to local recurrence after a period of an equilibrium created between proliferating, quiescent and dying cancer cells. The tumor microenvironment is a main obstacle for the efficacy of radiotherapy, as impaired blood flow leads to hypoxia, acidity and reduced accessibility of radiosensitizers. Eradication of remnant disease is an intractable clinical quest. After more than a century of research, anti-tumor...
ConclusionIn Caucasian AEG/S patients, 17.1% appeared to be eligible for an anti-Claudin 18.2 therapy. Claudin 18.2 expression itself has no impact on prognosis and is not related to any tumor subtype. (Source: Clinical and Translational Oncology)
ConclusionsThe number of metastatic lymph nodes and PSA doubling time seems to be important prognostic factors in the pelvic oligorecurrent setting. Salvage radiotherapy combined with short-course ADT might be a valid treatment strategy. (Source: Clinical and Translational Oncology)
ConclusionsLiver SBRT is a safe and effective treatment that achieves high local control rates. We found a significant correlation between larger LMCRC and worse local control. (Source: Clinical and Translational Oncology)
AbstractThe management of genitourinary cancer, including bladder, prostate, renal and testicular cancer, has evolved dramatically in recent years due to a better understanding of tumour genetic mutations, alterations in molecular pathways, and to the development of new kinds of drugs such as targeted therapies and immunotherapies. In the field of immunotherapy, new drugs focused on stimulating, enhancing and modulating the immune system to detect and destroy cancer, have been recently discovered....
AbstractWith advances in checkpoint inhibitor and CAR T-cell therapies, among other advances in immunotherapy, this is an exciting time to be a tumor immunologist. We are witnessing the transition of decades of work at the bench leading to substantial success in the clinic. While work continues developing new and improving existing immunotherapies, there remains a great deal of basic tumor immunology still to learn, information that can only lead to greater success in the clinic. One area in need...
ConclusionsThe SEOM considers it necessary to reduce the differences identified, increase homogeneity, and improve conditions of access to oncology drugs and biomarkers, and makes proposals to address these issues. (Source: Clinical and Translational Oncology)
ConclusionOur study suggests the potential specific PFAAs in sarcoma patients. The unusual amino acids and metabolic pathways may provide ideas for clinical drugs targeting therapy. Three amino acids including Car, GABA and Abu may be metabolic biomarkers playing a role in dynamic monitoring of the therapeutic effect. (Source: Clinical and Translational Oncology)
ConclusionEveryday group consensus peer review is an efficient manner to recollect clinical and technical data of cases presented to ensure quality radiation care before initiation of treatment as well as ensuring department quality in a feedback team environment. This model is feasible within the normal operation of every radiation oncology Department. (Source: Clinical and Translational Oncology)
ConclusionsFHOD3 was associated with overall survival time in medulloblastoma patients and was essential to cell proliferation, growth and survival in medulloblastoma and might regulates activation of RhoA/ROCK1/LIMK1 signaling pathway. (Source: Clinical and Translational Oncology)
ConclusionsThis study found that hsa_circ_0121582 was involved in the inhibition of tumor proliferation, and the restoration of hsa_circ_0121582 could be an effective treatment strategy for patients with leukemia. (Source: Clinical and Translational Oncology)
Mark above section as read
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου